(Q39019421)

8 September 2017

title

Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors (English)

1 reference

8 September 2017

main subject

hepatocellular carcinoma

1 reference

Sadahisa Ogasawara

1

1 reference

8 September 2017

Tetsuhiro Chiba

2

1 reference

8 September 2017

Yoshihiko Ooka

3

1 reference

8 September 2017

Naoya Kanogawa

4

1 reference

8 September 2017

Tomoko Saito

5

1 reference

8 September 2017

Tenyu Motoyama

6

1 reference

8 September 2017

Eiichiro Suzuki

7

1 reference

8 September 2017

Akinobu Tawada

8

1 reference

8 September 2017

Fumihiko Kanai

9

1 reference

8 September 2017

Osamu Yokosuka

10

1 reference

8 September 2017

publication date

12 April 2015

1 reference

Investigational New Drugs

8 September 2017

published in

1 reference

8 September 2017

volume

33

1 reference

8 September 2017

issue

3

1 reference

8 September 2017

page(s)

729-739

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-015-0237-3

8 September 2017

exact match

0 references

cites work

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0237-3

Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25861764

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25861764

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25861764

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-015-0237-3

1 reference

8 September 2017

1 reference